Cargando…

The development and trial of a medication discontinuation program in the department of forensic psychiatry

BACKGROUND: When treating mentally ill criminal offenders, improving medication adherence is essential to achieving goals, such as long-term stabilization of symptoms and the prevention of recidivism. Most subjects who are treated under the Medical Treatment and Supervision Act have schizophrenia, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Murasugi, Kenji, Tsukahara, Teruomi, Washizuka, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363327/
https://www.ncbi.nlm.nih.gov/pubmed/25788969
http://dx.doi.org/10.1186/s12991-015-0049-z
_version_ 1782361895370489856
author Murasugi, Kenji
Tsukahara, Teruomi
Washizuka, Shinsuke
author_facet Murasugi, Kenji
Tsukahara, Teruomi
Washizuka, Shinsuke
author_sort Murasugi, Kenji
collection PubMed
description BACKGROUND: When treating mentally ill criminal offenders, improving medication adherence is essential to achieving goals, such as long-term stabilization of symptoms and the prevention of recidivism. Most subjects who are treated under the Medical Treatment and Supervision Act have schizophrenia, which is considered a particularly difficult disorder for which to improve medication adherence. For such patients, we developed a Medication Discontinuation Program (MDP) that aims to improve medication adherence by discontinuing antipsychotic drugs and monitoring changes in psychiatric symptoms. We examined whether there was any utility for the MDP on a trial basis as well as whether it would be worthwhile to introduce the MDP to psychiatric programs. METHODS: We conducted the MDP with an intervention group (n = 7) and compared Drug Attitude Inventory-30 (DAI-30) scores before and after implementation of the MDP. We also categorized 30 questions of the DAI-30 into three subscales: “awareness of the need for medication”, “awareness of the effects of psychiatric drugs”, and “impression of medication”, and examined factors affecting improvement in medication adherence. RESULTS: The total DAI-30 score significantly increased after completion of the MDP (P = 0.002). Significant elevations after completion of the MDP were also observed in the scores for three subscales of the DAI-30. CONCLUSIONS: Our study suggests that the MDP has a possibility of improving medication adherence, and this program might have multidirectional and stimulatory effects on each factor related to the improvement of medication adherence.
format Online
Article
Text
id pubmed-4363327
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43633272015-03-19 The development and trial of a medication discontinuation program in the department of forensic psychiatry Murasugi, Kenji Tsukahara, Teruomi Washizuka, Shinsuke Ann Gen Psychiatry Primary Research BACKGROUND: When treating mentally ill criminal offenders, improving medication adherence is essential to achieving goals, such as long-term stabilization of symptoms and the prevention of recidivism. Most subjects who are treated under the Medical Treatment and Supervision Act have schizophrenia, which is considered a particularly difficult disorder for which to improve medication adherence. For such patients, we developed a Medication Discontinuation Program (MDP) that aims to improve medication adherence by discontinuing antipsychotic drugs and monitoring changes in psychiatric symptoms. We examined whether there was any utility for the MDP on a trial basis as well as whether it would be worthwhile to introduce the MDP to psychiatric programs. METHODS: We conducted the MDP with an intervention group (n = 7) and compared Drug Attitude Inventory-30 (DAI-30) scores before and after implementation of the MDP. We also categorized 30 questions of the DAI-30 into three subscales: “awareness of the need for medication”, “awareness of the effects of psychiatric drugs”, and “impression of medication”, and examined factors affecting improvement in medication adherence. RESULTS: The total DAI-30 score significantly increased after completion of the MDP (P = 0.002). Significant elevations after completion of the MDP were also observed in the scores for three subscales of the DAI-30. CONCLUSIONS: Our study suggests that the MDP has a possibility of improving medication adherence, and this program might have multidirectional and stimulatory effects on each factor related to the improvement of medication adherence. BioMed Central 2015-02-27 /pmc/articles/PMC4363327/ /pubmed/25788969 http://dx.doi.org/10.1186/s12991-015-0049-z Text en © Murasugi et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
Murasugi, Kenji
Tsukahara, Teruomi
Washizuka, Shinsuke
The development and trial of a medication discontinuation program in the department of forensic psychiatry
title The development and trial of a medication discontinuation program in the department of forensic psychiatry
title_full The development and trial of a medication discontinuation program in the department of forensic psychiatry
title_fullStr The development and trial of a medication discontinuation program in the department of forensic psychiatry
title_full_unstemmed The development and trial of a medication discontinuation program in the department of forensic psychiatry
title_short The development and trial of a medication discontinuation program in the department of forensic psychiatry
title_sort development and trial of a medication discontinuation program in the department of forensic psychiatry
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363327/
https://www.ncbi.nlm.nih.gov/pubmed/25788969
http://dx.doi.org/10.1186/s12991-015-0049-z
work_keys_str_mv AT murasugikenji thedevelopmentandtrialofamedicationdiscontinuationprograminthedepartmentofforensicpsychiatry
AT tsukaharateruomi thedevelopmentandtrialofamedicationdiscontinuationprograminthedepartmentofforensicpsychiatry
AT washizukashinsuke thedevelopmentandtrialofamedicationdiscontinuationprograminthedepartmentofforensicpsychiatry
AT murasugikenji developmentandtrialofamedicationdiscontinuationprograminthedepartmentofforensicpsychiatry
AT tsukaharateruomi developmentandtrialofamedicationdiscontinuationprograminthedepartmentofforensicpsychiatry
AT washizukashinsuke developmentandtrialofamedicationdiscontinuationprograminthedepartmentofforensicpsychiatry